Stearylalkohol | 51166-26-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Stearylalkohol
• 英文别名: 1-methoxy-heptadecane；1-Methoxyheptadecane
• CAS: 51166-26-8
• 化学式: C₁₈H₃₈O
• 分子量: 270.499
• InChiKey: NAECPPVCMWIIDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  19
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Stearylalkohol 在 potassium dihydrogenphosphate 、 一水合硫酸镁 、 盐酸硫胺 、 monosodium glutamate 作用下， 以 aq. phosphate buffer 、 十二烷 为溶剂， 以41 %的产率得到(Z)-1-methoxyheptadec-8-ene
  参考文献：
  名称：

  直链烷烃的选择性末端官能化**

  摘要：

  据报道，一种两步序贯策略，涉及生物催化脱氢/远程加氢官能化作为一种​​统一且通用的方法，选择性地将直链烷烃转化为大量有价值的官能化脂肪族衍生物。该反应在直链烷烃的非反应性伯 CH 键处进行位点选择性官能化，并避免使用直链 α-烯烃。

  DOI：

  10.1002/anie.202306343
• 作为产物：
  描述：

  甲醇 、 十七烯 在 mercury(II) diacetate 、 sodium 作用下， 以 甲醇 为溶剂， 以89%的产率得到2-Methoxyheptadecane
  参考文献：
  名称：

  Kaur, Navdeep; Dhillon, Ranjit S., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2001, vol. 40, # 4, p. 327 - 328

  摘要：

  DOI：

文献信息

• ISOCYANATE PRODUCTION PROCESS
  申请人：Shinohata Masaaki

  公开号：US20110092731A1

  公开（公告）日：2011-04-21

  An object of the present invention is to provide a process that enables isocyanate to be produced stably over a long period of time and at high yield without encountering problems of the prior art during production of isocyanate without using phosgene. The present invention discloses a process for producing an isocyanate by subjecting a carbamic acid ester to a thermal decomposition reaction, including the steps of: recovering a low boiling point component in a form of a gaseous phase component from a thermal decomposition reaction vessel in which the thermal decomposition reaction is carried out; recovering a liquid phase component containing a carbamic acid ester from a bottom of the thermal decomposition reaction vessel; and supplying all or a portion of the liquid phase component to an upper portion of the thermal decomposition reaction vessel.

  本发明的一个目的是提供一种能够在长时间内稳定地高产且不使用光气的情况下生产异氰酸酯的方法，而不会遇到先前生产异氰酸酯时的问题。本发明公开了一种通过将氨基甲酸酯经受热分解反应来生产异氰酸酯的方法，包括以下步骤：从进行热分解反应的反应釜中回收形成气相组分的低沸点组分；从热分解反应釜底部回收含有氨基甲酸酯的液相组分；并将全部或部分液相组分供给至热分解反应釜的上部。
• Amino alcohol derivatives
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030236297A1

  公开（公告）日：2003-12-25

  Compounds of formula (I) which exhibit excellent immune suppression activity, pharmacologically acceptable salts thereof, esters thereof or other derivatives: 1 wherein R 1 and R 2 are a hydrogen atom, an amino protecting group; R 3 is a hydrogen atom, a hydroxy protecting group; R 4 is a lower alkyl group; n is an integer from 1 to 6; X is an ethylene group; Y is a C 1 -C 10 alkylene group, a C 1 -C 10 alkylene group substituted with 1 to 3 substituents selected from substituent group a and b; R 5 is an aryl group; R 6 and R 7 are a hydrogen atom, a group selected from substituent group a; with the proviso when R 5 is a hydrogen atom, Y is not a single bond or a straight chain C 1 -C 10 alkylene group.

  式（I）的化合物表现出优异的免疫抑制活性，其药理学上可接受的盐，酯或其他衍生物：其中R1和R2是氢原子，氨基保护基；R3是氢原子，羟基保护基；R4是较低的烷基基团；n是1到6之间的整数；X是乙烯基团；Y是C1-C10烷基基团，带有1到3个从取代基a和b中选择的取代基的C1-C10烷基基团；R5是芳基基团；R6和R7是氢原子，从取代基a中选择的基团；但是当R5是氢原子时，Y不是单键或直链的C1-C10烷基基团。
• Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these
  申请人：Nishi Takahide

  公开号：US20050043386A1

  公开（公告）日：2005-02-24

  Amino alcohol compounds and phosphonic acid compounds having excellent immunosuppressive activity, pharmacologically acceptable salts thereof and pharmacologically acceptable esters thereof, and pharmaceutical compositions comprising such compounds, the compounds having the following formula: wherein R 1 and R 2 each represent hydrogen, or a protecting group of the amino group; R 3 represents hydrogen, or a protecting group of the hydroxyl group; R 4 represents a lower alkyl group; n is 1 to 6; X represents oxygen or nitrogen, which is unsubstituted or substituted with a lower alkyl group; Y represents ethylene; Z represents a C 1 -C 10 alkylene; R 5 represents an aryl group; and R 6 and R 7 each represents hydrogen; provided that when R 5 represents hydrogen, then Z represents a group other than a single bond or a straight chain C 1 -C 10 alkylene group.

  具有出色的免疫抑制活性的氨基醇化合物和膦酸化合物，其药理学上可接受的盐和药理学上可接受的酯，以及包含这些化合物的制药组合物，其中化合物具有以下式子：其中R1和R2各代表氢，或氨基保护基；R3代表氢，或羟基保护基；R4代表较低的烷基；n为1至6；X代表氧或氮，未取代或取代为较低的烷基；Y代表乙烯；Z代表C1-C10烷基；R5代表芳基；R6和R7各代表氢；但是当R5代表氢时，Z代表除单键或直链C1-C10烷基组以外的一种基团。
• Amino alcohol compounds
  申请人：Nishi Takahide

  公开号：US20070105933A1

  公开（公告）日：2007-05-10

  A method for the preventing a disease selected from the group consisting of rheumatoid arthritis and psoriasis in a mammal, such as a human, in need thereof, which includes administering to the mammal a pharmaceutically effective amount of a compound of formula (Ia) wherein R 1 and R 2 are each hydrogen; R 3 is hydrogen; R 4 is C 1 -C 2 alkyl; n is 2; X is=N-D, wherein D is hydrogen, C 1 -C 4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2 or phenylene; Z is ethylene or trimethylene; R 5 is an unsubstituted C 3 -C 10 cycloalkyl, an unsubstituted C 6 -C 10 aryl, or a C 3 -C 10 cycloalkyl or C 6 -C 10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6 and R 7 are each hydrogen.

  本发明涉及一种用于预防哺乳动物，例如人类，需要预防风湿性关节炎和银屑病等疾病的方法，包括向哺乳动物内部给予化合物（Ia）的药物有效量，其中R1和R2均为氢; R3为氢; R4为C1-C2烷基; n为2; X为=N-D，其中D为氢、C1-C4烷基或苯基; Y为乙烯基、乙炔基、-CO-CH2或苯基; Z为乙烯基或三亚甲基; R5为未取代的C3-C10环烷基、未取代的C6-C10芳基或取代有1-3个取代基的C3-C10环烷基或C6-C10芳基，所述取代基选自卤素、低碳基、卤代低碳基和低烷氧基的群体; R6和R7均为氢。
• Method for treating a immunology-related disease
  申请人：Nishi Takahide

  公开号：US20090326038A1

  公开（公告）日：2009-12-31

  A method for treating an immunology-related disease. The method involves administering to a mammal in need thereof a pharmaceutically effective amount of an amino acid compound, a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof. The compound has the following formula: , wherein R 1 and R 2 are each hydrogen; R 3 is hydrogen; R 4 is C 1 -C 2 alkyl; n is 2; X is ═N-D, wherein D is hydrogen, C 1 -C 4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2 or phenylene; Z is ethylene or trimethylene; R 5 is unsubstituted C 3 -C 10 cycloalkyl, unsubstituted C 3 -C 10 aryl, or C 3 -C 10 cycloalkyl or C 6 -C 10 aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6 and R 7 are each hydrogen.

  一种治疗免疫相关疾病的方法。该方法涉及向需要治疗的哺乳动物中注射药物有效量的氨基酸化合物，其药理学上可接受的盐或其药理学上可接受的酯。该化合物具有以下式子：其中R1和R2均为氢；R3为氢；R4为C1-C2烷基；n为2；X为═N-D，其中D为氢、C1-C4烷基或苯基；Y为乙烯、乙炔基、—CO—CH2或苯基；Z为乙烯或三亚甲基；R5为未取代的C3-C10环烷基、未取代的C3-C10芳基或取代有1至3个卤素、低烷基、卤代低烷基和低烷氧基的C3-C10环烷基或C6-C10芳基；R6和R7均为氢。